FY2027 Earnings Forecast for ESPR Issued By Zacks Research

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research upped their FY2027 EPS estimates for Esperion Therapeutics in a research note issued to investors on Tuesday, May 27th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of $0.10 per share for the year, up from their prior forecast of $0.09. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

ESPR has been the topic of a number of other reports. Needham & Company LLC cut their price objective on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Friday, April 25th. The Goldman Sachs Group cut their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $4.00 target price (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $6.25.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR traded down $0.02 during midday trading on Thursday, reaching $0.85. 4,498,295 shares of the company traded hands, compared to its average volume of 5,457,480. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $3.94. The stock has a 50-day moving average price of $1.00 and a 200 day moving average price of $1.74. The company has a market cap of $169.34 million, a price-to-earnings ratio of -1.34 and a beta of 0.75.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $54.97 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ESPR. Summit Financial LLC increased its stake in Esperion Therapeutics by 18.2% in the 4th quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company's stock worth $102,000 after purchasing an additional 7,150 shares in the last quarter. Foundations Investment Advisors LLC increased its stake in Esperion Therapeutics by 48.6% in the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock worth $66,000 after purchasing an additional 9,872 shares in the last quarter. Private Advisor Group LLC increased its stake in Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 10,000 shares in the last quarter. Invesco Ltd. increased its stake in Esperion Therapeutics by 15.5% in the 4th quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company's stock worth $215,000 after purchasing an additional 13,101 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock worth $7,956,000 after purchasing an additional 16,100 shares in the last quarter. 47.39% of the stock is owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.